Literature DB >> 2345431

Norepinephrine clearance, chromogranin A and dopamine beta hydroxylase in renal failure.

M G Ziegler1, B Kennedy, E Morrissey, D T O'Connor.   

Abstract

Plasma norepinephrine (NE) levels are normal or elevated in patients with renal failure even though uremia often damages the sympathetic nerves that release NE. We infused 3H-NE into subjects with normal, mildly depressed, or absent renal function. 3H-NE clearance was depressed 20% in mild renal failure and 40% in patients on hemodialysis. The calculated rate of NE release into plasma was low in uremics even though their plasma NE was normal. Dopamine beta hydroxylase (D beta H) and chromogranin A are released from sympathetic nerve endings along with NE. D beta H levels were low in uremia and D beta H levels doubled following hemodialysis. Chromogranin A levels were very high in uremics and increased slightly following hemodialysis. Plasma clearance of both NE and chromogranin A appears low in renal failure. The calculated rate of NE release is diminished in uremics, which is in accord with reports of autonomic neuropathy in these patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2345431     DOI: 10.1038/ki.1990.122

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  12 in total

1.  Undegraded chromogranin A is present in serum and enters the endocytotic lysosomal pathway in kidney.

Authors:  R Weiler; H J Steiner; R Fischer-Colbrie; K W Schmid; H Winkler
Journal:  Histochemistry       Date:  1991

Review 2.  Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations.

Authors:  P Reetze-Bonorden; J Böhler; E Keller
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

Review 3.  Chromogranin A and the tumor microenvironment.

Authors:  Angelo Corti
Journal:  Cell Mol Neurobiol       Date:  2010-11-16       Impact factor: 5.046

4.  Serum chromogranin A concentration and intradialytic hypotension in chronic haemodialysis patients.

Authors:  Ilona Kurnatowska; Michał Nowicki
Journal:  Int Urol Nephrol       Date:  2006-12-11       Impact factor: 2.370

5.  Chromogranin A polymorphisms are associated with hypertensive renal disease.

Authors:  Rany M Salem; Peter E Cadman; Yuqing Chen; Fangwen Rao; Gen Wen; Bruce A Hamilton; Brinda K Rana; Douglas W Smith; Mats Stridsberg; Harry J Ward; Manjula Mahata; Sushi K Mahata; Donald W Bowden; Pamela J Hicks; Barry I Freedman; Nicholas J Schork; Daniel T O'Connor
Journal:  J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 10.121

Review 6.  Clinical significance of serum biomarkers in pediatric solid mediastinal and abdominal tumors.

Authors:  John A Sandoval; Linda H Malkas; Robert J Hickey
Journal:  Int J Mol Sci       Date:  2012-01-20       Impact factor: 6.208

7.  Heritable influence of DBH on adrenergic and renal function: twin and disease studies.

Authors:  Dalal N Pasha; Jason T Davis; Fangwen Rao; Yuqing Chen; Gen Wen; Maple M Fung; Manjula Mahata; Kuixing Zhang; Danuta Trzebinska; Maja Mustapic; C Makena Hightower; Michael S Lipkowitz; Ming Ji; Michael G Ziegler; Caroline M Nievergelt; Daniel T O'Connor
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

8.  Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms.

Authors:  Andrea Corsello; Luigi Di Filippo; Sara Massironi; Federica Sileo; Anna Dolcetta Capuzzo; Marco Gemma; Claudia Carlucci; Claudio Cusini; Barbara Colombo; Alice Dallatomasina; Giulia Maria Franchi; Angelo Corti; Marco Federico Manzoni
Journal:  PLoS One       Date:  2018-05-03       Impact factor: 3.240

9.  Cardiovascular and renal effects of bromocriptine in diabetic patients with stage 4 chronic kidney disease.

Authors:  Oliva Mejía-Rodríguez; Jorge E Herrera-Abarca; Guillermo Ceballos-Reyes; Marcela Avila-Diaz; Carmen Prado-Uribe; Francisco Belio-Caro; Antonio Salinas-González; Helios Vega-Gomez; Cleto Alvarez-Aguilar; Bengt Lindholm; Elvia García-López; Ramón Paniagua
Journal:  Biomed Res Int       Date:  2013-08-04       Impact factor: 3.411

10.  Mast cell activation syndrome as a significant comorbidity in sickle cell disease.

Authors:  Lawrence B Afrin
Journal:  Am J Med Sci       Date:  2014-12       Impact factor: 2.378

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.